PO.CL01.19 · 临床研究

结合生物信息学、深度学习分析与免疫组织化学的方法,以确定晚期糖基化终末产物(AGER)复合物蛋白在结肠癌进展中的生物标志物潜力

A combined bioinformatics, deep learning analysis, and immunohistochemistry approach to define the biomarker potential of advanced glycosylated end products (AGER) complex proteins in colon cancer progression

海报缩略图:结合生物信息学、深度学习分析与免疫组织化学的方法,以确定晚期糖基化终末产物(AGER)复合物蛋白在结肠癌进展中的生物标志物潜力
编号 2540 展板 15 时间 4/20 09:00–12:00 区域 Section 44 主讲 Jorge Alberto Guadarrama-Orozco, MD
分会场 Early Detection Biomarkers 2
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Jorge Alberto Guadarrama-Orozco1, Monica Serrano Arevalo2, Ariadna Heredia Pulido3, Jennifer Ramirez-Puente4, José Diaz-Chavez2

1Tijuana General Hospital, Tijuana, Mexico,2Instituto Nacional de Cancerologia, Ciudad de Mexico, Mexico,3Oncos Patologia Tijuana, Tijuana, Mexico,4Hospital Angeles Tijuana, Tijuana, Mexico

摘要 Abstract

中文摘要
背景:尽管结直肠癌(CRC)的诊断和人群筛查项目近年来取得了进展,但识别具有癌前病变或早期CRC分期的患者仍然具有挑战性,而这对于降低CRC发病率和提高患者生存率至关重要。 方法:本研究通过生物信息学数据挖掘流程(STRING、UALCAN、HPA、GEPIA2、TNMplot)、其相互作用分析(DMFold-Multimer),并辅以实验验证,全面研究了AGER复合物蛋白/N-糖基化基因(DDOST、PRKCSH和GALECTIN 3)与结肠癌进展在结直肠癌中的临床意义及相互关系。我们分析了112例来源于CRC I至IV期的结直肠组织样本,包括正常组织和腺瘤。使用免疫组织化学在正常组织、癌前病变和CRC分期递增的癌性病变上对三个候选生物标志物进行了表征。我们在QuPath中选择感兴趣区域(ROI),并使用DeepLIIF扩展程序在ImageJ中进行分析以计算表达百分比。 结果:PRKCSH、DDOST和GALECTIN 3的分布在组织中得到了验证,与正常组织和癌前组织相比,它们表现出不同的表达水平,尤其是在CRC的早期阶段。 结论:我们重点指出了三种蛋白,它们需要进一步研究,以更好地表征其在早期CRC癌变中的作用以及作为CRC进展标志物的潜力。
查看英文原文 English abstract
Background: Despite recent advances in colorectal cancer (CRC) diagnosis and population screening programs, the identification of patients with preneoplastic lesions or with early CRC stages remains challenging and is essential for reducing CRC incidence and increasing patients' survival. Methods: Our study comprehensively investigated the clinical significance and relationship among AGER complex protein/N-Glycosilation genes (DDOST, PRKCSH, and GALECTIN 3) and colon cancer progression in colorectal cancer through a bioinformatics data mining process (STRING, UALCAN, HPA, GEPIA2, TNMplot), their interaction (DMFold-Multimer), and followed by experimental validation. We analyzed 112 colorectal tissue samples originating from CRC stages I to IV, including normal tissue and adenomas. The characterization of three biomarker candidates was performed using immunohistochemistry on normal tissue, precancerous, and cancerous lesions with increasing CRC stages. We selected the ROI in QuPath and analysed it in ImageJ using the DeepLIIF extension to calculate expression percentage. Results: The distributions of PRKCSH, DDOST, and GALECTIN 3 were validated in tissues, showing different expression levels, especially in early stages of CRC, compared to normal and preneoplastic tissues. Conclusion: We highlighted three proteins that require further investigation to better characterize their role in early CRC carcinogenesis and their potential as markers of CRC progression.
利益披露 Disclosure
J. Guadarrama-Orozco, None.. M. Serrano Arevalo, None.. A. Heredia Pulido, None.. J. Ramirez-Puente, None.. J. Diaz-Chavez, None.

← 返回 AACR 2026 检索